Progress on non-infection-related eye diseases of patients with human immunodeficiency virus/acquired immune deficiency syndrome

doi:10.3877/cma.j.issn.1674-1358.2023.06.007

Abstract

Abstract:

Acquired immune deficiency syndrome (AIDS) is caused by human immunodeficiency virus (HIV), which affects multiple systems and can lead to health problems that cannot be ignored. Common eye diseases in HIV/AIDS patients may cause vision loss, visual field loss and possibly binocular blindness, affecting the quality of daily life of patients. HIV/AIDS-related eye diseases have a wide range of manifestations, including vascular diseases, tumors, neuro-ophthalmic diseases, immune reconstructive inflammatory syndrome, adverse drug reactions, and non-AIDS-defined eye diseases, etc. This article reviews non-infection-related eye diseases of HIV/AIDS patients.

Key words: Human immunodeficiency virus, Acquired immune deficiency syndrome, Eye disease

Ke Chen, Huiyu Sun. Progress on non-infection-related eye diseases of patients with human immunodeficiency virus/acquired immune deficiency syndrome[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(06): 395-399.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2023.06.007

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2023/V17/I06/395

References 38

[1]	Saini N, Hasjia S, Kaur P, et al. Study of prevalence of ocular manifestations in HIV positive patients[J]. Nepal J Ophthalmol,2019, 11(21):11-18.
[2]	World Health Organization. HIV and AIDS[EB/OL]. URL
[3]	Lo PF, Lim R, Antonakis SN, et al. Progressive outer retinal necrosis: manifestation of human immunodeficiency virus infection[J]. BMJ Case Rep,2015:bcr2014207344.
[4]	吴苑妮, 张健, 宋心成, 等. 人类免疫缺陷病毒/获得性免疫缺陷综合征相关性眼病的研究进展[J/CD]. 中华实验和临床感染病杂志(电子版),2020,14(2):93-98.
[5]	Chen C, Guo CG, Meng L, et al. Comparative analysis of cytomegalovirus retinitis and microvascular retinopathy in patients with acquired immunodeficiency syndrome[J]. Int J Ophthalmol, 2017,10(9):1396-1401.
[6]	Li LJ, Tan P, Hee O, et al. Brief report: retinal microvasculature and immune restoration among South Eastern Asian patients with HIV/AIDS over a 9-month antiretroviral therapy[J]. J Acquir Immune Defic Syndr,2022,90(2):170-174.
[7]	Jabs DA, Van Natta ML, Pak JW, et al. Association of retinal vascular caliber and age-related macular degeneration in patients with the acquired immunodeficiency syndrome[J]. Invest Ophthalmol Vis Sci,2018,59(2):904-908.
[8]	Tounouga DN, Kouotou EA, Nansseu JR, et al. Epidemiological and clinical patterns of Kaposi sarcoma: A 16-year retrospective cross-sectional study from Yaoundé, Cameroon[J]. Dermatology, 2018,234(5-6):198-204.
[9]	Radu O, Pantanowitz L. Kaposi sarcoma[J]. Arch Pathol Lab Med,2013,137(2):289-294.
[10]	Venkateswaran N, Ramos JC, Cohen AK, et al. Spotlight on ocular Kaposi’s sarcoma: an update on the presentation, diagnosis, and management options[J]. Expert Rev Ophthalmol,2021,16(6):477-489.
[11]	Donovan C, Patel H, Shetty S, et al. Aggressive conjunctival Kaposi sarcoma as the initial manifestation of acquired immunodeficiency syndrome[J]. Am J Ophthalmol Case Rep,2020,19(16):100832.
[12]	Re A, Cattaneo C, Rossi G. HIV and lymphoma: from Epidemiology to Clinical Management[J]. Mediterr J Hematol Infect Dis,2019,11(1):e2019004.
[13]	Vaccher E, Gloghini A, Carbone A. HIV-related lymphomas[J]. Curr Opin Oncol,2022,34(5):439-445.
[14]	Berhan A, Bayleyegn B, Getaneh Z. HIV/AIDS associated lymphoma: review[J]. Blood Lymphat Cancer,2022,12(29):31-45.
[15]	Steffen J, Coupland SE, Smith JR. Primary vitreoretinal lymphoma in HIV infection[J]. Ocul Immunol Inflamm,2021,29(3):621-627.
[16]	鲁丹, 孙挥宇, 毛菲菲, 等. HIV感染合并原发性眼眶淋巴瘤二例[J]. 眼科,2019,28(4):258-259.
[17]	Nanji AA, Mercado C, Galor C, et al. Updates in ocular surface tumor diagnostics[J]. Int Ophthalmol Clin,2017,57(3):47-62.
[18]	Henry RK, Bagg A, Wu C, et al. Orbital and ocular adnexal manifestations of adult T-cell leukemia/lymphoma: a case report and systematic review[J]. Ophthalmic Plast Reconstr Surg,2021,37(3):201-211.
[19]	Di Y, Xu HY, Ye JJ, et al. Clinical features and treatment outcomes of intraocular lymphoma: a single-center experience in China[J]. Int J Ophthalmol,2021,14(4):574-581.
[20]	鲁丹, 王胜男, 毛菲菲, 等. HIV/AIDS患者合并眼部肿瘤的临床特征分析[J]. 眼科,2021,30(6):474-476.
[21]	Gordon LK, Danesh-Meyer H. Neuro-ophthalmic manifestations of HIV infection[J]. Ocul Immunol Inflamm,2020,28(7):1085-1093.
[22]	Sudharshan S, Nair N, Curi A, et al. Human immunodeficiency virus and intraocular inflammation in the era of highly active anti retroviral therapy--An update[J]. Indian J Ophthalmol,2020,68(9):1787-1798.
[23]	Sadik, MT, Aksu Ceylan N, Cebeci Z, et al. Patterns of cytomegalovirus retinitis at a tertiary referral center in Turkey[J]. Int Ophthalmol,2021,41(9):2981-2992.
[24]	Liu Q, Xu ZY, Wang XL, et al. Changes in conjunctival microbiota associated with HIV infection and antiretroviral therapy[J]. Invest Ophthalmol Vis Sci,2021,62(12):1.
[25]	Qian Y, Wang L, Jiang J, et al. Cytomegalovirus-immune recovery retinitis after initiation of highly active antiretroviral Therapy: A Case Series[J]. Front Med,2022,9(27):807013.
[26]	Han Y, Wu N, Zhu W, et al. Detection of HIV-1 viruses in tears of patients even under long-term HAART[J]. AIDS,2011,25(15):1925-1927.
[27]	Di Y, Zhao XY, Ye JJ, et al. Fundus manifestations and HIV viral loads of AIDS patients before and after HAART[J]. Int J Ophthalmol, 2019,12(9):1438-1443.
[28]	Qian Y, Wu Z, Chen C, et al. Detection of HIV-1 viral load in tears of HIV/AIDS patients[J]. Infection,2020,48(6):929-933.
[29]	毛菲菲, 孙挥宇, 李丹, 等. 获得性免疫缺陷综合征合并人类免疫缺陷病毒视网膜病变的眼底病变特征分析[J]. 中华眼底病杂志,2012,28(6):585-587.
[30]	Fisher KM, Montrief T, Ramzy M, et al. Cryptococcal meningitis: a review for emergency clinicians[J]. Intern Emerg Med,2021,16(4):1031-1042.
[31]	Nallu R, Madhavan P, Chirch L, et al. Thyroid eye disease due to immune reconstitution inflammatory syndrome as a consequence of antiretroviral therapy in the setting of AIDS[J]. Case Rep Endocrinol, 2020,2020:1728423.
[32]	Jin KW, Lee JY, Rhiu S, et al. Longitudinal evaluation of visual function and structure for detection of subclinical Ethambutol-induced optic neuropathy[J]. PLoS One,2019,14(4):e0215297.
[33]	Ando T, Kage H, Matsumoto Y, et al. Lower dose of ethambutol may reduce ocular toxicity without radiological deterioration for Mycobacterium avium complex pulmonary disease[J]. Respir Investig,2021,59(6):777-782.
[34]	Chuwongwattana S, Jantararoungtong T, Prommas S, et al. Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections[J]. Pharmacol Res Perspect,2020,8(6):e00665.
[35]	Orssaud C, Guillemain R, Lillo Le Louet A. Toxic optic neuropathy due to voriconazole: possible potentiation by reduction of CYP2C19 activity[J]. European Rev Med Pharmacol Sci,2021,25(24):7823-7828.
[36]	Testi I, Agarwal A, Agrawal R, et al. Drug-induced uveitis in HIV patients with ocular opportunistic infections[J]. Ocul Immunol Inflamm,2020,28(7),1069-1075.
[37]	Sereti I, Altfeld M. Immune activation and HIV: an enduring relationship[J]. Curr Opin HIV AIDS,2016,11(2):129-130.
[38]	Singalavanija T, Ausayakhun S, Tangmonkongvoragul C. Anterior segment and external ocular disorders associated with HIV infections in the era of HAART in Chiang Mai University Hospital, a prospective descriptive cross sectional study[J]. PLoS One,2018,13(2):e0193161.

Please choose a citation manager

Content to export